Printer Friendly

CONNAUGHT LABORATORIES, INC. TO DISTRIBUTE JAPANESE ENCEPHALITIS VIRUS VACCINE INACTIVATED

 SWIFTWATER, Penn., Dec. 18 /PRNewswire/ -- Connaught Laboratories, Inc. (CLI), of Swiftwater, Penn., announced that it will begin distributing JE-VAX(TM) (Japanese Encephalitis Virus Vaccine Inactivated) under an exclusive agreement with the manufacturer, The Research Foundation for Microbial Diseases of Osaka University ("BIKEN(R)). JE-VAX provides active immunization against Japanese encephalitis (JE) and is indicated for certain persons who live in or are traveling to highly endemic or epidemic areas during periods of virus activity.
 "CLI has a long history as a provider of vaccines such as Menomume(R) for meningitis and YF-VAX(R) for Yellow Fever that are utilized by travelers and our armed forces," said David J. Williams, president and COO of Connaught Laboratories, Inc. "We are proud to add JE-VAX to our product line."
 JE is a mosquito-borne viral encephalitis, which may occur in epidemics in late summer and autumn in the temperate regions and in the northern part of tropical zones of Bangladesh, Burma, China, India, Japan, Kampuchea, Korea, Laos, Nepal, Thailand and eastern areas of the Commonwealth of Independent States (formerly USSR). In areas where JE is endemic, and there is no seasonal pattern, the risk is lower, but occasional outbreaks do occur. These areas include the tropical zones of southern India, Indonesia, Malaysia, Philippines, Singapore, Sri Lanka, Taiwan and southern Thailand
 Availability and Dosage
 For initial immunization older than three years of age, a series of three 1.0 mL doses are administered subcutaneously. For children one year to three years of age, the dose should be decreased to 0.5 mL for each administration. A schedule of Day 0, Day 7, and Day 30 is recommended for optimal immunogenicity. An "accelerated" schedule of Day 0, Day 7, and Day 14 may be used in urgent situations, although a compressed schedule may be associated with a slightly higher incidence of side effects and lower antibody titers.
 A booster dose of 1.0 mL (0.5 mL for children from 1 to 3 years of age) may be given after two years. In the absence of firm data on the persistence of antibody after primary immunization, a definite recommendation cannot be made on the spacing of boosters beyond two years.
 Reactions to vaccination include headache, malaise, local pain, local redness and swelling. Allergic reactions, manifesting as generalized urticaria and angioedema, may occur from minutes to as long as ten days after immunization and may be serious enough, in some cases, to require immediate medical attention. Recipients are advised to remain in an area where medical care is available for up to ten days after immunization. Rarely, serious neurologic disorders have occurred in temporal association with immunization.
 JE-VAX is supplied in single dose vials (5 per package) with Diluent (5 per package) as well as a 10-dose vial with a vial of Diluent.
 The vaccine, prior to reconstitution, should be stored between 2 degrees to 8 degrees Centigrade (35 degrees to 46 degrees Fahrenheit). It should not be frozen. After reconstitution, the vaccine should be held at 2 degrees to 8 degrees Centigrade and be used within 8 hours and must not be stored. Reconstituted vaccine should not be frozen.
 Connaught Laboratories, Inc., a Pasteur Merieux Company, provides the broadest range of vaccines and biologicals commercially available in the United States from a single company. CLI is headquartered in Swiftwater, Penn., where the company is actively involved in the field of immunological research and its applications. In addition, approximately 560 employees are engaged in manufacturing, marketing and distributing vaccines against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, influenza, yellow fever, rabies and other disease. CLI is a wholly owned subsidiary of Connaught Laboratories, Limited, of Toronto, Canada, a member of the Pasteur Merieux group of companies, the world's largest developer and manufacturer of vaccines for human use.
 -0- 12/18/92
 /NOTE TO EDITORS: To obtain a copy of the product package insert, please call Lenore Cooney or Beth Waters at 212-929-1400/
 /CONTACT: Beth Waters or Lenore Cooney of Cooney-Waters Group, 212-929-1400, for Connaught Laboratories/


CO: Connaught Laboratories ST: Pennsylvania IN: MTC SU: PDT

LD-TM -- NY004 -- 8050 12/18/92 08:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1992
Words:687
Previous Article:BON JOVI PERFORMS THIRD ANNUAL HOLIDAY BENEFIT
Next Article:CLOSING OF $560 MILLION INVESTMENT GRADE RATED COSO PROJECT DEBT REFINANCING
Topics:


Related Articles
CONNAUGHT LABORATORIES, INC. RECEIVES ACELLULAR DTP VACCINE LICENSE
CONNAUGHT LABORATORIES PRESIDENT ON CLINTON IMMUNIZATION PROPOSAL
EDUCATION AND OUTREACH BETTER SOLUTIONS TO CHILDHOOD IMMUNIZATION PROBLEM THAN UNIVERSAL PURCHASE
CONNAUGHT LABORATORIES DONATES TETANUS VACCINES TO IOWA FLOOD VICTIMS; TETANUS RISK EXPECTED TO ESCALATE AS CLEAN-UP INTENSIFIES
CONNAUGHT LABORATORIES DONATES TETANUS VACCINES TO IOWA FLOOD VICTIMS; TETANUS RISK EXPECTED TO ESCALATE AS CLEAN-UP INTENSIFIES
CONNAUGHT LABORATORIES' LYME DISEASE VACCINE ENTERS PHASE THREE CLINICAL TRIALS
VAXCEL ANNOUNCES OPTION AGREEMENT WITH CONNAUGHT
CONNAUGHT APPLIES TO FDA FOR LICENSING OF FIRST ACELLULAR PERTUSSIS VACCINE TO BE USED IN COMBINATION WITH HIB VACCINE FOR INFANTS
OraVax Acquires Chimeric Vaccine Technology From St. Louis University Patent Filing Covers a New Class of Single-Dose Viral Vaccines
OraVax Unveils New ChimeriVax Family of Vaccines Against Major Disease Targets

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters